More News! 10 Dec 2018 British Company Raises €37M to Personalize Therapies with Machine Learning Genomics, a company based in Oxford, has increased the amount raised in a Series B round that will fund further development of its genomics technology for personalized medicine. The company adds a further €9M (£8M) to the round with the participation of Foresite Capital and F-Prime Capital, two renowned US life sciences investors. The previous […] December 10, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2018 Orchard’s Gene Therapy for Rare Immune Disease Works for Over a Year A single dose of a gene therapy developed by Orchard Therapeutics can restore immune function for at least a year in patients with X-linked chronic granulomatous disease (X-CGD). The gene therapy was trialed in patients between the ages of 2 and 27 with the rare disease, which is caused by a rare genetic mutation that […] December 7, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Startup Scout 7 Dec 2018 This Hypoallergenic Vaccine Could Alleviate Hay Fever Faster Than Approved Vaccines We decided to make a visit to Espoo, Finland, this week, to visit Desentum. The company is developing allergy vaccines that could be safer and faster than approved vaccines. Mission: To make a vaccine that decreases the time taken to reduce allergies compared with approved vaccines, which contain the natural allergen. Desentum plans to do […] December 7, 2018 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2018 UK Project Hits 100,000 Genomes Target In a step forward for the world of personalized medicine, the UK Government-backed 100,000 Genomes Project has reached its sequencing target. The project, which is one of the largest of its kind, was designed to collect genomic data to improve the capacity of personalized medicine, as well as learning more about the genetic basis of […] December 6, 2018 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2018 Update: Liver Gene Therapy 8 Times Stronger Than Usual Update (06/12/2018): uniQure has incorporated Synpromics’ strong liver promoter into a preclinical gene therapy candidate for treating hemophilia A. Published on 08/10/2018 Synpromics and uniQure have unveiled new technology for precise genetic control that could make gene therapy safer and more precise. The team has developed a gene therapy system that is highly selective for […] December 6, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Inside Labiotech 6 Dec 2018 We Are Now More Than 150,000 Awesome Biotechers Every Month Woohooo! We’ve hit 150,000 unique visitors per month to our site! What a beautiful number. We are so happy to be able to bring you great content every day and have our biotech network grow with more amazing people. Why this makes us so happy? Because it means that, 150,000 different people stopped by our website […] December 6, 2018 - 2 minutesmins - By Editorial Team Share WhatsApp Twitter Linkedin Email
News and Trends 5 Dec 2018 Llama-Inspired Antibodies Succeed in Clinical Trials and Financial Deal Autoimmune disease and acute myeloid leukemia may have a llama-inspired antibody treatment one day. The Dutch company argenx’s antibodies have shown positive results in clinical trials, and have attracted Janssen into a collaboration to advance their use in cancer immunotherapy. In a phase II trial, the company’s lead antibody, efgartigimod, reduced the number of bleeding […] December 5, 2018 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 5 Dec 2018 How Automation Will Enable the Age of Cell Therapy Scientists in biotech and pharma spend more and more of their valuable time culturing cells manually. Automated cell culture is still not standard in the early research stages, and many believe that needs to change. Philip talked to Ali Afshar, co-founder of Cytera Cellworks to discuss how the main obstacles to bringing automation to cell […] December 5, 2018 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 4 Dec 2018 Gene Therapies for Blood Disorders Marching Through the Clinic Gene therapy holds great potential as a cure for blood disorders such as hemophilia and sickle cell disease, which have limited treatment options. This week, several gene therapy companies have released promising clinical trial results in hemophilia and sickle cell anemia. Presenting at the 2018 annual meeting of the American Society of Hematology, Dutch company uniQure […] December 4, 2018 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 4 Dec 2018 Microbiome Therapy Shows Early Promise in Cancer Patients A clinical trial run by MaaT Pharma has shown that restoring the microbiome of patients undergoing chemotherapy has potential to improve the outcome of patients with the blood cancer acute myeloid leukemia (AML). The microbes living in our gut can have a big influence on the success of cancer treatments. Some microorganisms are known to […] December 4, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 3 Dec 2018 First-in-Class Cancer Drug Gets €50M Boost The biopharmaceutical company Aprea Therapeutics has raised €50M to fund a Phase III trial of its first-in-class cancer drug candidate, which kills tumor cells by restoring the function of a key anti-cancer protein called p53. Aprea’s planned Phase III trial will test the company’s lead candidate small molecule drug combined with the chemotherapy drug azacitidine. […] December 3, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 30 Nov 2018 Update: UK Biotech Scores £5M Series A to Boost Next-Generation Cancer Antibodies Update (30/11/2018): IGEM Therapeutics has increased the total raised in Series A to £5M (€5.6M) with the participation of two new investors, Alsa Holdings and UCL Technology Fund. The funding will go towards the development of a new generation of antibody drugs for cancer. Published on 20/06/2017 IGEM Therapeutics has raised £2M (€2.3M) in Series A […] November 30, 2018 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email